479In that regard, it is appropriate to point out that the lack of any action against the use of other substances, even if assumed to be unlawful, could not in itself affect the lawfulness of the ban on virginiamycin (see, to that effect, Safety Hi-Tech, cited at paragraph 152 above, paragraph 41). It has been held above that the institutions were entitled to withdraw the authorisation of virginiamycin as an additive in feedingstuffs in the overriding interest of public health protection. Consequently, even if Pfizer had established that the authorisations of other products should also be withdrawn for reasons corresponding to the one which has prevailed in this case, it would not have proved that the contested regulation was unlawful for breach of the principle of non-discrimination, in so far as there is no equality in illegality, since the principle of non-discrimination does not found an entitlement to the non-discriminatory application of unlawful treatment.